[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo, AstraZeneca
DS-8201: Regulatory submission in EU for HER2 positive breast cancer in Q1 FY 2020 (Daiichi Sankyo) - Aug 1, 2019 - Q1 FY 2019 Results: Regulatory submission in Japan for HER2 positive gastric cancer in Q1 FY 2020 
European regulatory • Japanese regulatory
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005447/FY2019Q1_Presentation%20Material.pdf
 
Aug 1, 2019
 
 
35c5fd6a-9a8e-44d8-b7c4-39fee69c254b.jpg